PMID: 6163491Jan 1, 1981Paper

Tetrodotoxin potentiation of the antiarrhythmic action of lidocaine in the late stage of experimental myocardial infarct

Biulleten' eksperimental'noĭ biologii i meditsiny
L V RozenshtraukhG G Beloshapko

Abstract

Lidocaine (4--12 mg/kg) and the specific fast sodium current blocker tetrodotoxin (TTX) (1--6 mg/kg, i. v.) reduced ventricular arrhythmias that occurred 24 h after coronary artery ligation in dogs. Infusion of a mixture of subthreshold doses of lidocaine and TTX decreased ventricular arrhythmias to the same degree as infusion of threshold doses of either agent alone. This finding suggests that the antiarrhythmic action of lidocaine in the late stage of myocardial infarction is due to inhibition of the fast inward, sodium current. The possible mechanisms of rhythm disturbances in the late stage of myocardial infarction are discussed.

References

Jun 1, 1979·Cardiovascular Research·R RuffyD P Zipes
Mar 16, 1979·Pflügers Archiv : European journal of physiology·D AttwellC Ojeda
May 1, 1978·The American Journal of Cardiology·R LazzaraB J Scherlag
Jan 1, 1975·Circulation Research·J KupersmithB F Hoffman
Jan 1, 1973·Circulation Research·M R Rosen, B F Hoffman
Oct 1, 1980·Biulleten' eksperimental'noĭ biologii i meditsiny·L V RozenshtraukhS A Dremin

❮ Previous
Next ❯

Citations

Jun 1, 1991·Biulleten' eksperimental'noĭ biologii i meditsiny·E I GendenshteĭnV E Oleĭnikov

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.